Given the frequent coexistence of obesity and T2D with cardiovascular disease and chronic kidney disease (CKD), incretin-based therapies (encompassing selective GLP-1 and multi-receptor agonists) have emerged as disease-modifying treatments across the cardiovascularkidneymetabolic (CKM) spectrum
doi: 10.1016/j.bbadis.2016.04.007
Additionally, patients initiating treatment with semaglutide 1 mg may have received higher doses of their baseline GLP-1 RA, meaning that the improvements brought by switching to semaglutide were comparatively less pronounced in these patients
Emerging research suggests GLP-1s may directly affect the skin by reducing collagen production, accelerating glycation (which stiffens and weakens collagen fibers), and diminishing hydration levels
Allergen Notice: Products in our stores may contain, or may have been exposed to, one or more of the following allergens: peanuts, tree nuts, sesame, milk, eggs, wheat, soy, fish and crustacean shellfish.
